三阴乳腺癌的治疗新进展

Advances in the treatment of triple-negative breast cancer

三阴乳腺癌是乳腺癌的一种特殊亚型，侵袭性强、预后差，除化疗外几乎没有其他的治疗措施。标准的辅助化疗和新辅助化疗应用蒽环类、环磷酰胺和紫杉醇类药物。许多研究报道了三阴乳腺癌的分子学特性，由此，我们可针对一些靶点来进行治疗。对铂类药物治疗三阴乳腺癌，尤其是BRCA基因突变的三阴乳腺癌的实验数据分析发现铂类药物在治疗中占主导作用。除此之外，我们回顾近期的药物试验数据，讨论聚ADP核糖聚合酶抑制剂、雄激素受体抑制剂等的作用。

Triple-negative breast cancer is a specific subtype of breast cancer, which shows strong ag- gressivenessand poor prognosis. There are few treatment measures except chemotherapy. Standard adjuvant chemotherapy and neoadjuvant chemotherapy include the application of anthracyelines, cyclophosphamide, and taxanes. Researches have reported the molecular characterization of triple-negative breast cancer. Thus, targeted therapy could be employed. We review the experimental data of thetherapy fortriple-negative breast cancer, es- pecially these with BRCA mutations. Platinum-based therapy wasdominant in these data. Besides, we also re- view the recent data of clinicaltrials and discuss the function of poly-ADP-ribose polymerase（PARP） inhibitors and androgen receptor（AR） inhibitors.